Why Zymeworks Inc.’s (ZYME) Stock Is Up 6.35%
As of Wednesday, August 19, Zymeworks Inc.’s ZYME share price has surged by 6.35%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Commentary & Analysis
Is Zymeworks Inc. (ZYME) Overvalued?
We dive into why Zymeworks Inc. (ZYME) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why Zymeworks Inc.’s (ZYME) Stock Is Down 5.26%
As of Friday, July 10, Zymeworks Inc.’s ZYME share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Zymeworks Inc.’s (ZYME) Stock Is Up 7.93%
As of Tuesday, June 30, Zymeworks Inc.’s ZYME share price has surged by 7.93%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Zymeworks Inc.’s (ZYME) Stock Is Down 7.56%
As of Monday, June 29, Zymeworks Inc.’s ZYME share price has dipped by 7.56%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,885.4 | $286.3 | 53% |
|
| Shares Out (Mil) | 73.0 | 54.2 | 56% |
|
| Institutional Ownership | 96.9% | 92.8% | 72% |
|
| Float (Mil) | 65.8 | 39.7 | 53% |
|
| Beta | 1.15 | 0.94 | 69% |
|
| Avg Daily Volume (000s) | 574 | 534 | 60% |
|
| Price Change (52-week) |
88.4% | 58.7% | 89% |
|
| Growth | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.1% | 13.6% | 83% |
|
| Net Income (5yr) | 14.8% | (10.1%) | 63% |
|
| EPS (5yr) | 21.4% | 16.0% | 70 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.6%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 5 | 6 | |
| Current EPS | $1.612 | $1.122 | $1.177 | |
| Month Ago EPS | $2.100 | $1.400 | $0.284 | |
| # Rev Up | 1 | 2 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $1.934 | $1.375 | $0.516 | |
| Year/Year Chg | (360.0%) | (204.1%) | (114.4%) | |
| Financials | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $37 | $37 | 18% |
|
| Net Income (TTM) (Mil) | ($150) | ($43) | 8% |
|
| EPS (TTM) | ($2.008) | ($1.400) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($119) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $81 | $2 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $1,364 | $160 | 44% |
|
| Valuation | ZYME | Industry Median |
Percentile (All Stocks) |
|
| P/B | 23.51 | 2.77 | 96% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (246.7%) | 64.2% | 1% |
|
| Net Margin | (404.0%) | (75.9%) | 2% |
|
| ROA | (37.2%) | (47.3%) | 15% |
|
| ROE | (72.3%) | (55.0%) | 12% |
|
| Liabilities to Assets | 79.8% | 29.6% | 74% |
|
| F-Score | 2 | 2 | 7% |
|
Zymeworks Inc. did not pass any screens on 8/20/2026.
